To test this, we examined Necdin expression in low malignancy potential (LMPs) versus aggressive ovarian cancer (TOVs), two distinct types of serous ovarian cancer thought to have different molecular origins, and where p53 mutations rarely (in LMPs) or frequently (in TOVs) occur [48], [49]. This evidence concerns the gene TP53 and ovarian cancer.